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INTRODUCTION 
 Coronary heart disease has been defined as "impairment of heart 
function due to inadequate blood flow to the heart compared to its needs, 
caused by obstructive changes in the coronary circulation to the heart"1. 
 It is the cause of 25-30% of death is most of the industrialised countries. 
In India also it is a major public health problem. 
 It is aptly called by WHO as the modern epidemic. The increasing 
incidence of coronary heart disease may be a reflection of increased longevity, 
adoption of high-fat diet based on meats, decreased exercise, modern life style, 
made possible by increasing affluence. 
 It is not surprising to note that Sir William Osler devoted only a few 
pages in his text book of medicine, published in 1892, to the discussion of 
Acute Myocardial Infarction. 
 It was the brilliant work of Herrick in 1912, who performed autopsy on 
Acute Myocardial Infarction patients that putforward the new concept of 
thrombotic occlusion of coronary artery as the cause of downstream necrosis of 
heart muscle. 
 Definitive proof for the above said concept came from angiographic 
studies performed during the early hours of the acute coronary event2. 
 This prompted scientists to systematically test the thrombolytic 
strategies to treat Acute Myocardial Infarction, opening that new era of 
thrombolytic therapy in Acute Myocardial Infarction. 
 Scientists have developed many effective thrombolytic drugs like, 
streptokinase, recombinant tissue plasminogen activator (rt PA), Reteplase 
(rPA), urokinase, APSAC (Anisoylated plasminogen streptokinase activator 
complex) etc. 
 Evidence for the use of thrombolytic therapy came from large multi 
centre studies3. GISSI and ISIS-2 confirmed reduction in mortality with the 
early use of streptokinase5. ISAM (intravenous streptokinase in Acute 
Myocardial Infarction study group) also stands as a proof of efficacy of 
thrombolytic drugs to reduce mortality. 
 Success rate of thrombolysis and thus the overall reduction in mortality 
is different among different agents used6. The GUSTO-1 trial showed a 30 day 
mortality of 6.3% for accelerated t-PA versus 7.4% for streptokinase with 
intravenous heparin. 
 But because of the prohibitive cost of tPA, streptokinase became the 
sheet anchor for thrombolytic therapy in Govt. General Hospital. Thrombolytic 
therapy has revolutionized the management of Acute Myocardial Infaction7. 
GUSTO angiographic substudy showed a success rate of 54% at 90 minutes 
using IV streptokinase and Heparin. 
 Thrombolytic therapy has been consistently proven to reduce the 
mortality and morbidity. Inspite of this it has been recognised that thrombolytic 
therapy has failed in a significant population. There is lot of room for 
improvement. We need to identify the factors that are responsible for failure of 
thrombolysis. 
 In this background, we decided to look into our own patients who 
receive streptokinase for Acute Myocardial Infarction, in the coronary care unit 
of Govt. General Hospital. 
AIM OF STUDY 
1. To find out the overall success rate of thrombolysis in the coronary care 
unit of Govt. General Hospital. 
2. To find out whether the following parameters influence the outcome of 
thrombolysis. 
  a. Age 
  b. Sex 
  c. Time of Streptokinase administration 
  d. Pre-infarction angina 
  e. Alcohol intake 
  f. Smoking status 
  g. Pre existing systemic hypertension 
  h. Diabetes mellitus 
  i. Location of Myocardial infarction 
REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
Although the anginal syndrome was described in the 1770's, it was not 
until 1912 that Sir James B.Herrick described Acute Myocardial Infarction. 
In the landmark paper by Herrick, he wrote "The clinical manifestation 
of coronary obstruction will evidently vary greatly... depending on the size, 
location and number of vessels occluded. The symptoms and end results must 
also be influenced by blood pressure, by the condition of myocardium not 
immediately affected by obstruction, and by the ability of the remaining vessels 
to properly carryout their work, as determined by their health or disease"8. 
Most of his observations hold good even after 90 years. 
Levine published a book on coronary thrombosis in 1929. 
Only after the classic angiographic study of De Wood and colleagues 
from Spokane, who demonstrated thrombotic occlusion of coronary arteries in 
87% of patients within 4 hours of symptom onset, medical community was 
convinced that the proximate cause of Acute Myocardial Infarction is coronary 
thrombosis2. 
PATHOPHYSIOLOGY OF ACUTE MYOCARDIAL INFARCTION 
 Coronary atherosclerosis is the underlying substrate in nearly all patients 
with Acute Myocardial Infarction. 
 The hallmark of atherosclerotic coronary artery disease is the fibrous 
plaque. It has a fibrous cap, composed of smooth muscle cells and matrix, 
which covers a variable amount of lipid core, cell debris, macrophages, which 
may be filled with lipid, often intermixed with variable number of T 
lymphocytes. 
 Plaques are not uniform in their constitution. Plaque heterogeneity is 
important in that which plaque is prone to fissuring or cracking cannot be 
determined even by angiography. 
 Those plaques which have a thin fibrous cap, more number of 
macrophages and T cells, more lipid content and less number of smooth muscle 
cells are prone to rupture9. Smooth muscle cells appear to protect against 
plaque disruption, whereas macrophages and mononuclear cells, by elaborating 
proteolytic enzymes like matrix metallo proteinase, stromelysins, elastases tend 
to weaken the fibrous caps10. Mononuclear cells also elaborate monocyte 
chemotactic protein (MCP-1) which recruits more number of macrophages and 
mononuclear cells into the fibrous cap. 
WHAT PRECIPITATES PLAQUE DISRUPTION? 
 It is now proved beyond doubt that Acute Myocardial Infarction occurs 
as a result of disruption of a coronary artery plaque at a site of high density of 
inflammatory cells namely macrophages and T lymphocytes. Thus Acute 
Myocardial Infarction can be thought of as resulting from acute exacerbation of 
a chronic inflammatory response. Precipitating factors work by exacerbating 
that inflammatory response and/or increasing the physical forces impinging on 
a coronary artery lesion weakened by inflammation, leading rupture. 
1. Infections 
 An association has been noted between Acute Myocardial Infarction and 
antecedent mild respiratory syndromes. 
 Increased antibody titre to C.pneumoniae have been associated with 
increased risk of Acute Myocardial Infarction11. 
 Evidence exists for the presence of C.pneumoniae in atherosclerotic 
lesions. 
2. Emotional of Environmental Stress 
 Distressing or changing life events reportedly  occur with increased 
frequency in the months preceding a Myocardial Infarction12,13. It is apparent 
that any acute stressful event / Intervention can precipitate Acute Myocardial 
infarction in a patient with active, susceptible coronary atherosclerotic lesions. 
3. Circadian and seasonal variation 
 Peak incidence of Acute Myocardial Infarction is between 6 a.m. and 
noon. Underlying mechanism is thought to be the diurnal variation in 
sympathetic nervous system activity and thrombotic tendency. 
 In the morning hours there is an enhanced platelet aggregability and a 
trough in intrinsic fibrinolytic activity. Other factors contributing are the 
increased heart rate and increased coronary artery tone in the morning. PAI-I 
levels in blood is highest in the morning hours. 
THROMBUS FORMATION 
 Thrombus formation at the site of plaque disruption is the fundamental 
pathophysiological mechanism of unstable angina and Acute Myocardial 
Infarction. 
ROLE OF PLATELETS 
 This may be reviewed in 3 headings 
1. Platelet adhesion 
2. Activation with granular release 
3. Platelet aggregation 
Platelet Adhesion 
 Platelets adhere to the subendothelial collagen immediately. 
Glycoprotein Ib on the platelet membrane links with Von Willebrand Factor 
(vWF) in the subendothelial collagen. The membrane receptor complex Glyco 
protein IIb/IIIa bind a number of relevant protein, including vWF, fibrinogen 
and fibronectin. 
Platelet activation and Aggregation 
 Activated platelets release a number of substances like serotonin, ADP, 
PDGF (Platelet derived growth factor), Thrombospondin, vWF etc. 
 PDGF plays a role in the proliferation and migration of smooth muscle 
cells after vessel damage. Released ADP binds to the specific receptors that 
change the conformation of GpIIb/IIIa complex so that it binds vWF, 
fibrinogen, fibronectin, thus linking adjacent platelet into hemostatic plug. 
Coagulation cascade 
 Coagulation cascade plays a critical role in secondary hemostasis. Both 
intrinsic and extrinsic system take part in this process. 
Role of Intrinsic pathway 
 Exposure of factor XII to subendothelium activates it to factor XII a, 
which inturn activates factor XI to XIa. XIa converts factor IX to activated 
factor IXa. Factor IXa along with factor VIII and calcium converts factor X to 
factor Xa. From here it is a common pathway for both systems. 
Extrinsic pathway 
 This pathway is activated by interaction of tissue factor released from 
the damaged vessel wall and factor VII. Tissue thrombo plastin and factor VII 
activates factor X to Xa. 
 Factor Xa along with factor V and calcium ions converts prothrombin to 
thrombin. Thrombin has several functions the principal one being conversion 
of fibrinogen to fibrin. Thrombin also activates factor V, VIII; and XIII and 
stimulates platelet aggregation and secretion. Finally the fibrin polymer is 
stabilised by factor XIIIa resulting in an adherent thrombus. 
SYSTEMIC FACTORS FAVOURING THROMBOGENESIS 
1. Circulating catecholamines increases the platelet aggregability and 
thrombin generation 
Smoking and emotional factors may be operating by increasing the 
catecholamines level in blood. 
2. Elevated levels of homocysteine 
Is toxic to endothelium, decrease the capacity of endothelium to make 
nitric oxide and induces endothelial dysfunction. 
3. Diabetes Mellitus 
Apart from accelerated atherosclerosis, platelet activity and coagulation 
are increased in diabetics suggesting that it is a prothombotic state. PAI-I levels 
are also found to be higher in diabetics. 
4. Plasminogen Activator Inhibitor-I (PAI-I) 
High levels of PAI-I levels are associated with increased risk of Acute 
coronary syndromes. 
5. Elevated Apolipoprotein (a) 
May serve as a competitive inhibitor of plasminogen and cause a 
prothrombotic stage. 
6. Elevated fibrinogen and Factor VII 
Is yet another risk factor for thrombosis. Interestingly both are found to 
be elevated in advanced age, obesity, hyperlipidemia, diabetes, smoking and 
emotional stress. 
FIBRINOLYSIS 
 Fibrinolysis starts at the same time of thrombogenesis because elements 
of the fibrinolytic system are incorporated into the fibrin thrombus as it forms. 
COMPONENTS OF FIBRINOLYTIC SYSTEM 
1. Plasminogen and Plasmin 
 It is a single chain glycoprotein synthesised primarily by Liver. This is 
the precursor of the chief proteolytic enzyme plasmin. This conversion is 
facilitated by the binding of plasminogen to fibrin (thrombus). Plasmin is 
capable of proteolyzing not only fibrin but also other proteins like fibrinogen, 
coagulation factors V, VIII and extracellular matrix protein. 
2. Plasminogen activators 
 Intrinsic activators of plasminogen are Kallikrein and factor XIIa, which 
are direct activators. 
 Extrinsic activators are tissue type plasminogen activator (t-PA), High 
molecular weight-two chain urokinase, and low molecular weight-two chain 
urokinase. 
Exogenous activators 
 Are used therapeutically in Acute Myocardial Infarction. Streptokinase, 
APSAC, and staphylokinase belong to this category. 
TISSUE TYPE PLASMINOGEN ACTIVATOR 
 t-PA is synthesized predominantly by vascular endothelial cells. It is a 
serine protease. 
 In the absence of fibrin tPA has little activity, therefore t-PA mediated 
activation of plasminogen in plasma is minimal. Both single chain and two 
chain form of t-PA have proteolytic activity that is enhanced several hundred 
fold in the presence of fibrin. 
 Free plasmin in the plasma is rapidly neutralised by α2-plasmin 
inhibitor where as fibrin-bound plasmin in protected from α2 - plasmin 
inhibitor. 
UROKINASE TYPE PLASMIN ACTIVATORS 
 Urokinase is a serine protease that is synthesised in the kidney as well as 
in endothelial cells and initially released as a single chain urokinase or scu-PA. 
 Limited proteolysis by plasmin converts scu-PA to high molecular 
weight two chain urokinase (HMW tcUK). Like tPA, HMW tcUK also has 
relative fibrin selectivity but is enhanced only 10 times by the presence of 
fibrin. 
ENDOGENOUS INHIBITORS OF FIBRINOLYSIS 
 These inhibitors of plasminogen activators and plasmin belongs to 
serpin family. 
PLASMINOGEN ACTIVATOR INHIBITOR (PAI-I) 
Sources 
 Endothelial cells, hepatocyte, smooth muscle cells and plateletes. It is 
stored in platelet α-granules from which it can be readily released upon platelet 
activation. PAI-I is the predominant inhibitor of t-PA and urokinase in human 
plasma. It accounts for approximately 60% of the total plasminogen activator 
inhibitory capacity of plasma. 
 Thrombin induces PAI-I release from cultured human endothelial cells; 
so also endotoxin. During inflammatory states PAI-I levels are increased. 
 There is a diurnal variation in the circulating levels of PAI-I 
concentration which contribute to the clustering of Acute Myocardial Infarction 
during morning hours as well as morning resistance of thrombolytic therapy. 
 PAI-2 is found in placental tissue, where it plays a role in hemostasis. 
ALPHA2-PLASMIN INHIBITOR 
 This single chain glycoprotein directly inhibits plasmin. It is synthesized 
and secreted from hepatocytes. It is also stored in platelet α-granules. Alpha2-
plasmin inhibitor rapidly neutralises free plasmin in plasma. Where as fibrin 
bound plasmin is protected from its action. Alpha2-Plasmin inhibitor is 
incorporated into fibrin clots through cross-linking by factor XIIIa thereby 
preventing uncontrolled or premature fibrinolysis. 
PROTEIN C 
Actions 
 It inhibits the release of PAI-I from endothelial cells. 
 Inactivates PAI-I, factor Va, VIIa. 
Regulation of fibrinolysis 
 Net activation of plasminogen is the result of a delicate balance among 
zymogens; proteases; inhibitors and protease receptor on the cell surface. 
 Regulation and control of fibrinolysis occurs at several levels. Secretion 
of plasminogen activator and also plasminogen activator inhibitor from 
endothelium, enhancement of plasminogen activation by fibrin and plasmin 
inhibition by α-2 antiplasmin inhibition. In addition certain cell types such as 
endothelial cells, monocytes and platelets have receptors for plasminogen and 
plasminogen activators which when occupied enhance plasminogen activation 
and localise plasmin activity to the cell surface. By modulating the expression 
of these cell surface receptors, cellular regulation of fibrinolysis is possible. 
ACUTE MYOCARDIAL INFARCTION 
Symptoms 
 Prodromal symptoms are common, most of these symptoms are anginal 
or anginal like hours or days before the Acute cardiac event. 
 Retrosternal chestpain, associated with nausea, diaphoresis and 
dysponea is the cardinal symptom. Pain any radiate to medial aspect of left arm 
or to both arms. Other sites of radiation are neck or lower jaw, to epigastrium 
and back. 
 Duration should be more than 15 minutes. Occasionally presenting 
symptoms may be syncope, acute confusion, agitation, stroke or palpitations. 
Approximately 23% of Acute Myocardial Infarction go unnoticed by the 
patient because of lack of symptoms. Elderly can present as congestive cardiac 
failure without any history of pain. 
Physical findings 
 Patient may have an anxious look. Sweating may be excessive. 
 Pulse: Normal or increased rate may be noticed. Persistent sinus tachy 
cardia beyond the initial 12-24 hours is predictive of high mortality rate. 
 In patients with inferior Acute Myocardial Infarction upto 60% of 
patients will be having bradycardia in initial hours. 
Blood pressure 
 Hypotension can occur in inferior wall Acute Myocardial Infarction, 
with right ventricular involvement, and extensive anterior Acute Myocardial 
Infarction with cardiogenic shock. Hypertension may be a feature of anterior 
wall Acute Myocardial infarction. 
JVP 
 Elevated JVP is a feature of major RV infarction. Prominent `a' wave 
may occur because of the decreased compliance of right-ventricle. Kussmaul 
sign may also be seen in right ventricular infarction. 
PRECORDIAL EXAMINATION 
Palpation 
 Palpation in the left lateral position may reveals a diffuse apical impulse 
rather than a localised impulse. Apex may be dyskinetic also. Decreased 
compliance of left ventricle may give rise to presystolic expansion of apex 
corresponding to the auscultatory S4. 
Auscultation 
 First and second heart sounds are often very soft because of decreased 
contractility, prolonged PR interval or both. 
 A fourth heart sound is often audible. Third heart sound is heard in 
probably only about 15-20% of Acute Myocardial Infarction patients. 
 Ischemia of posteromedial papillary muscle can manifest as a crescendo-
decrescendo midsystolic murmur of mitral regurgitation. This murmur usually 
disappear after the first 12-24 hours if it is soft. But a loud or moderate 
intensity murmur may persist much longer or may be permanent. 
DIAGNOSIS 
Electrocardiography 
 Electrocardiographic criteria for diagnosing Acute Myocardial 
Infarction are the presence in the setting of chestpain of any one of the 
following. 
1. New or presumably new Q waves (atleast-30ms wide and 0.20 mv 
deep) in at least two leads from any of the following. (a) lead II, III, 
avF (b) Leads, V1-V6(c) leads I and aVL. 
2. New or presumably new ST-segment elevation or depression ≥ 
0.10mv measured 0.02 Sec. after J point in two contiguous leads of 
the above mentioned lead combination. 
3. Complete LBBB 
ELECTROCARDIOGRAPHIC ESTIMATE OF INFARCT SIZE 
 In general there is a direct relationship between the number of leads 
showing ST elevation and mortality. ST elevation in eight or nine lead is 
associated with a mortality of three to four times that of patients manifesting 
ST segment elevating in only two or three leads. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hyperacute phase of extensive Anterolateral myocardial 
infarction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute inferior wall `q' wave infarctions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute Right ventricular myocardial infarction with Acute 
inferior wall myocardial infarction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transthoracic Echo cardiography recorded in a patient with Acute 
anterior anteroseptal myocardial infarction. This tracing was 
recorded in a parasternal long axis view in diastole (Top) systole 
(Bottom). In the lower panel note the normal downward motion of 
the proximal portion of the ventricular septum and the dyskinesis of 
the more distal portion of the anterior septum (Upward Arrow).  
AO = Aorta, LA : Left atrium. 
 
 
 
 
 
 
 
DIAGNOSIS OF RIGHT VENTRICULAR MI BY SURFACE ECG 
ST-segment elevation in lead V4R is the single most powerful predictor of right 
ventricular involvement in Inferior wall Myocardial Infarction. 
 A new classification of AMI based on electrocardiographic entry 
criteria with angiographic correlation. 
Sl. 
No. 
Categories Anatomy of 
occlusion 
ECG 30 day 
mortality 
1 year 
mortality 
1. Proximal LAD Proximal to first septal 
perforator 
ST↑V1-V6, L1, aVL 
fascicular or bundle 
branch block 
19.6 25.6 
2. Mid LAD Distal to first septal 
perforator, proximal to 
large diagonal 
ST↑V1-V6, L1, aVL  9.2 12.4 
3. Distal LAD or 
diagonal 
Distal to large 
diagonal or of diagonal 
itself 
ST↑ V1-V4, or ST↑ 1, 
aVL L5-V6 
6.8 10.2 
4. Moderate to large 
inferior (posterior; 
lateral, right 
ventricular) 
Proximal RCA or left 
circumflex 
ST↑ II, III a aVF and 
any or all of following 
a. V1-V3, R, V4-R 
b. V5, V6 or  
c. R>s in V1, V2 
6.4 8.4 
5. Small inferior Distal RCA or left 
circumflex branch 
occlusion 
ST↑ II, III, a VF only 4.5 6.7 
 
 Based on GUSTO-I cohort population in each of the 5 categories, all 
receiving reperfusion therapy. 
CLINICAL SIGNIFICANCE OF ABOVE MENTIONED SURGROUPS 
 Proximal LAD Acute Myocardial infarction is often referred to as the 
widow-maker Acute Myocardial Infarction. It is often associated with LAHB, 
RBBB, bifascicular block, LBBB or mobitz type II AV block. Cardiogenic 
shock is not unexpected. 
MID LAD OCCLUSION 
• No conduction disturbances 
• Cardiogenic shock is less common, when shock is present one 
should consider prior Acute Myocardial Infarction or non cardiac 
causes like massive hemorrhage. 
DISTAL LAD OCCLUSION 
• Cardiogenic shock cannot results from this type of infarction 
perse. 
• But as in the above forms apical hypokinesis and LV thrombus 
formation can occur. 
SIGNIFICANCE OF RVMI 
• Here the occlusion is in the proximal RCA prior to the origin of 
right ventricular branch. 
• Mortality jumps from 6% in an isolated inferior wall Acute 
Myocardial Infarction to 25-30% when RV is involved. 
LOCATING THE INFARCT RELATED ARTERY IN INFERIOR 
WALL ACUTE MYOCARDIAL INFARCTION14 
• This is possible by looking at the ST depression in V3 and ST 
Elevation in L III. 
• ST depression in V3 in maximal in LCX obstruction which 
produce less ST elevation in L III. 
• On the contrary proximal RCA obstruction leads to maximal 
elevation in L III and lesser ST depression in V3. 
• By dividing ST depression in V3 by ST elevation in L III a ratio 
V3/III is obtained which, if <0.5 identifies proximal RCA 
occlusion; 0.5-1.2 distal RCA occlusion and >1.2 identifies LCX 
occlusion. 
HEMODYNAMIC CLASS (KILLIP) 
 Killip classification is the most useful simple method to assign patients 
into hemodynamic classes. 
Class I 
 No evidence of heart failure. 85% of Acute Myocardial Infarction 
patients present in this class.  
Class II 
 Early evidence of heart failure manifested by S3, bibasilar rales (less 
than 50% of lung fields). 10% of people present in this category. 
Class III 
 Frank pulmonary edema 
Class IV 
 Cardiogenic shock. Only 5% of people with Acute Myocardial 
Infarction presents in class III or IV category. 
ENZYMATIC CRITERIA FOR DIAGNOSIS OF ACUTE 
MYOCARDIAL INFARCTION 
1. Serial increase then decrease of plasma MB-CK with change of 
>25% between any two values. 
2. MB-CK>10-13 U/L or >5% of total CK activity. 
3. Increase in MB-CK activity>50% between any two samples 
separated by at least 4 hours. 
4. If only a single sample available, MB-CK elevation>two fold. 
5. Beyond 72 hours, an elevation of troponin T or troponin I or LDH-
I>LDH2. 
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
 Immediately begin continuous cardiac monitoring for patients with 
suspected ischemic type of chest pain and obtain intravenous access. 
 Administer morphine, oxygen, nitroglycerine, and aspirin (MONA) to 
patients without contra indication. 
OXYGEN: INDICATIONS 
Class I 
1. Overt pulmonary congestion 
2. Arterial O2 desaturation (SaO2<90%) 
Class IIa 
1. Routine administration of O2 to all patients which uncomplicated 
Acute Myocardial Infarction during the first 2-3 hours. 
Class  IIb 
 Routine administration of supplemental O2 to patients with 
uncomplicated Acute Myocardial Infarction beyond 3-6 hours. 
ANALGESIA 
1. Morphine sulphate 2-4 mg every 15 minutes IV till adequate 
analgesia is obtained. 
2. In those with inferior wall Acute Myocardial Infarction vagolytic 
drug meperidine may be substituted. 
NITROGLYCERIN  
Class I :  
1. Patients with ongoing ischaemic discomfort should receive 
sublingual Nitroglycerin (0.4mg). 
2. Intravenous Nitroglycerin is indicated for releif of ongoing 
ischaemic discomfort, control of hypertension or Management of 
pulmonary congestion. 
Class III : 
1. Nitrates should not be administered to pations with systolic  BP < 
90 mmHg / RVMI. 
2. Nitrates should not be administered to pts who have received 
sildenafil with in the last 24 hr. 
Treatment should be initiated with a bolus injection of 12.5-25 µg and 
then followed by infusion by pump of 10-20µg/min with increases of 5-10µg 
every 5-10 minutes while assessing hemodynamic response. Control of 
symptoms is a major end point. In the case of high LV filling pressure, a 
decrease of 10-30% in PCWP is the objective. Or a decrease of 10% mean 
arterial pressure in normotensive and 30% decrease  in hypertensive may be the 
objective. Systolic B.P. should be above 90mm Hg and heart rate should not 
exceed 110/mt 
ASPIRIN 
 Aspirin 160-325 mg should be chewed as early as possible by all Acute 
Myocardial Infarction patients. Those with profound nausea, vomiting may be 
treated with aspirin suppositories (325 mg). 
BETA BLOCKERS 
Class I 
1. Patients with out a contraindication to β-blocker therapy who can be 
treated within 12 hours of onset of infarction, irrespective of the 
administration of concomitant thrombolytic therapy. 
2. Patients with continuing or recurrent ischemic pain. 
3. Patients with tachyarrhythmia, such as atrial fibrillation with a rapid 
ventricular response. 
Class IIb 
 1. Non Q wave Acute Myocardial Infarction. 
 Beta blockers interfere with the positive inotropic and chronotropic 
effects of catecholamines thus reducing afterload (blood pressure) and 
therefore myocardial O2 consumption. 
 It reduces ventricular ectopics, atrial fibrillation and nonfatal cardiac 
arrest. 
 Reduces frequency of progression of threatened infarction to completed 
infarction. 
 Reduces recurrent ischemia and infarction during first 6 weeks after 
initial events. 
TRIAGE INTO ELECTROCARDIOGRAPHIC SUBGROUPS 
 Using 12 lead ECG patients are triaged into 3 groups. 
1. ST- segment elevation 
2. ST-segment depression (≥1 mm) 
3. Non diagnostic 
It is important to note that development of `q' waves is not taken into 
consideration as far as thrombolytic therapy is considered. 
In one study 53% of patients presenting within one hour of symptoms 
already had Q waves. This early development of `q' wave appears to predict the 
infarct size but may not negate beneficial effects of fibrinolytic therapy on 
mortality or myocardial salvage. Q waves are often found to disappear 
following successful thrombolytic treatment. 
Patients with ischemic type chest pain and ST segment elevation ≥ 1 
mm in 2 contiguous leads have 45% sensitivity but 98% specificity for Acute 
Myocardial Infarction. 
Patients with ischemic type of chest pain but normal or non-diagnostic 
ECGs or ECGs consistent with ischemic (ST-depression only) do not benefit 
from fibrinolytic therapy. 
REPERFUSION STRATEGY 
 Reperfusion methods now in vogue are intravenous thrombolytic 
therapy, percutaneous transluminal coronary angioplasty and emergency 
coronary artery bypass grafting. 
Thrombolytic therapy: Indications 
Class I 
1. ST elevation (greater than 0.1 mv in two or more contiguous limb 
leads and/or ≥0.2 mv in any two contiguous chest leads at anytime 
during the observation period). Time to therapy 12 hours or less 
since the onset of continuous chest pain, discomfort, causing hospital 
presentation. Age less than 75 years. 
2. Left Bundle branch block (obscuring ST segment analysis) and 
history suggesting Acute Myocardial Infarction. 
Class IIa 
 ST elevation, age 75 years or older. 
Class IIb 
1. ST elevation as above, time to therapy greater than 12 hours but less 
than 24 hours. Thrombolysis can be considered in the case of 
ongoing pain and marked ST-segment elevation although there is 
only a trend for benefit under these circumstances in clinical trials. 
2. Blood pressure on presentation greater than 180mmHg of systolic 
and/or greater than 110 mm Hg diastolic with a high risk of Acute 
Myocardial Infarction. Here the risk of intracranial bleeding is high. 
Lowering the B.P. before administering Thrombolytics have been 
recommended but is of unproven benefit. If available coronary artery 
by pass grafting or primary PTCA should be considered. 
Class III 
1. ST segment elevation; time to therapy greater than 24 hours; 
ischemic pain resolved. 
2. ST depression only 
CONTRA INDICATIONS TO THROMBOLYTIC THERAPY 
Sl.No. Absolute Relative 
1. Active internal bleeding History of non hemorrhagic CVA 
in distant past with complete 
recovery 
2. Intracranial neoplasm or recent 
head trauma 
Recent trauma or surgery >2 wks 
previously 
3. Prolonged, traumatic CPR Active peptic ulcer disease 
4. Suspected aortic dissection Hemorrhagic retinopathy 
5. Pregnancy History of severe hypertension 
with diastolic BP>100 
6. History of hemorrhagic CVA 
or recent non hemorrhagic 
cerebrovascular accident. 
Bleeding diathesis or concurrent 
use of anticoagulant 
7. Recorded blood pressure 
>200/120 mmHg 
Previous treatment with SK or 
APSAC if being considered 
(doesnot apply to rtPA) 
8. Trauma or surgery that is a 
potential bleeding source 
within previous 2 weeks 
 
9. Allergy to SK or APSAC if 
being considered 
 
 
HISTORY OF THROMBOLYSIS 
 Human blood has long been known to contain fibrinolytic activity. Well 
over 110 years ago Denys and Zimmerman observed that the fibrin of human 
blood obtained from wet cupping dissolved in 12 to 24 hours. Dastre coined the 
term fibrinolysis. 
 The property of spontaneous thrombolytic was used by Yudin of Russia 
who used blood from fresh corpses (who were previously healthy; but died of 
accidents) for transfusion. 
 In 1933 Tilet and Garner at the John Hopkin's medical school 
demonstrated that filtrates of broth cultures of certain strains of hemolytic 
streptococcus contained a substances capable of inciting rapid fibrinolysis of 
human plasma clots. They named it streptococcal fibrinolysin. 
 Christensen renamed it streptokinase in 1945. He demonstrated that SK 
activates an inactive precursor of a proteolytic enzyme, later found to be 
plasminogen. 
 Streptokinase was clinically used first in 1947 by Tillet and Sol Sherry 
in a young man who developed loculated bloody effusion in the left pleural 
cavity following pneumonectomy. The response was dramatic in that all the 
loculation were broken down and a lysed coagulum was drained. 
 First clinical trial for Acute Myocardial Infarction recruited 24 patients 
and they found those treated early after the onset of infarction did better than 
those treated late16.  
 But only in 1977 FDA approved streptokinase and urokinase for clinical 
use in USA-which opened the new era of reperfusion therapy. 
THROMBOLYTIC DRUGS 
Non Fibrin Selective agents 
Streptokinase 
 It is a single chain polypeptide that lacks the serine residue required for 
enzymatic activity but it can activate plasminogen to plasmin after forming an 
equimolar complex with it. 
 Since it is not fibrin selective, extensive conversion of circulating 
plasminogen to plasmin occurs with subsequent depletion of fibrinogen, 
plasminogen and factors V and VIII from blood stream. 
 The accumulation of fibrin degradation products, depletion of 
circulating α2 antiplasmin, and hyperplasminemia that occur constitute a 
systemic lytic state. 
 Circulating half life of SK is 18-25 minutes. However depletion of 
fibrinogen to less than 50% of baseline values persists for approximately 24 
hours. 
 Antibodies to SK appears quickly and reaches high value by 5 days and 
remains above baseline for upto 30 months. So repeated administration is not 
recommended. 
ADVERSE EFFECTS 
• Hypotension is the most common which ranges from 10-40% of 
administrations. 
• Allergic reactions reported included fever, chills, urticaria, rash, 
flushing and muscle pain. 
• Minor bleeding can occur especially from vascular puncture and 
access site. Manual compression for 30 minutes or until bleeding 
stops is usually effective. 
• Intracranial bleeding is the dreaded complication. 
• Total stroke incidence in GISSI/international trial was 0.9% In 
ISIS 3 trial it was 1%. 
MODE OF ADMINISTRATION AND DOSAGE 
 1.5 million units of SK is administrated over 1 hour is the standard 
regimen. More rapid administration can lead to hypotension and should be 
avoided. 
Urokinase 
 Is an endogenous trypsin like enzyme. It is a direct plasminogen 
activator. It is present in urine and occurs in two forms in blood and tissues as a 
high molecular weight form and a low molecular weight form. It is non fibrin 
selective, producing a systemic lytic state similar to that produced by SK. It is 
non immunogenic and can be administrated as an intravenous bolus or by 
infusion. The recommended dose for Acute Myocardial Infarction, is 1,500,000 
unit bolus followed by 1,500,000 units given over 90 minutes. 
RELATIVELY FIBRIN SELETIVE AGENTS: TISSUE TYPE 
PLASMINOGEN ACTIVATOR (t-PA) 
 tPA is an endogenous serine protease synthesized and secreted by 
human vascular endothelium and numerous other types of cells. Cloning and 
expression of tPA gene in E.coli lead to the large scale production of 
recombinant tPA since 1984. 
 Plasma T½ is only 5 minutes but fibrinolytic activity persists on and 
within clots for 7 hours. rt-PA is metabolised by liver. Plasminogen activator 
inhibitor-I (PAI-I) rapidly inactivates t-PA. Infused rtPA rapidly saturates PAI-
I levels seen in blood. Other slow inhibitors of rtPA in blood are CI esterase 
inhibitor and α2-antiplasmin. 
 rtPA is relatively fibrin specific, it has an affinity for fibrin bound 
plasminogen. But rtPA is also capable of depleting blood fibrinogen levels to 
as low as an 50% and elevating fibrinogen degradation products. It has no 
immunogenicity. 
ADVERSE EFFECTS 
 Incidence of intracranial hemorrhage and stroke is slightly higher with 
rtPA than with SK. In GISSI/international trail it was 1.2%. In ISIS-3 it was 
1.4% (total stroke incidence). 
DOSAGE 
 Front loaded regimen is a associated with a 91% patency rate at 90 
minutes and it is now approved by FDA. Here 15 mg IV bolus followed by 50 
mg IV infusion over 30 minutes followed by 35 mg over next 60 minutes is 
given. 
EFFECTS OF THROMBOLYTIC THERAPY ON MORTALITY 
 Thrombolytic therapy reduces 35 day mortality by 21% compared with 
conventional therapy. 
 When used within the first hour of symptoms it saves 34 lives per 1000 
treated patients but it is reduced to 16 lives per 1000 treated cases when used 7-
12 hours after the onset of symptoms. 
CHOICE OF DRUG 
(30 day mortality rate from GUSTO Trial) 
Sl.No. Regimen Mortality % 
1. SK and subcutaneous heparin 7.2% 
2. SK and intravenous heparin 7.4% 
3. Accelerated rt-PA and intravenous heparin 6.3% 
4. Combination rt-PA and SI without heparin 7.0 
 
 14% reduction in mortality rate was achieved with accelerated rt-PA 
regimen versus SK strategies (p=0.001). 
 The 1 year followup of GUSTO-I trail showed that the 1% lower 
mortality rate compared with SK was maintained, which provided further 
evidence that rt-PA is more effective than SK. 
 Alteplase (rt-PA) may have the greatest benefit in patients with large 
infarction and appears to pose a low risk of intracranial haemorrhage in 
younger patients who present early. SK appears to provide greater benefit in 
older patients with a smaller amount of myocardium at risk who present later 
and those with a greater risk to intracranial haemorrhage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patterns of response to fibrinolysis : A: failure of epicardial reperfusion can 
occur due to failure to induce a lytic state or due to mechanical factor at the site 
of occlusion failure ofmicrovascular reperfusion is due to a combination of 
platelet microthrombi followed by endothelial swelling and myocardial edema 
"No reflow" B : Fibrinolysis may fail due to persistent occlusion of the epicardial 
infarct related artery (TIMI grade 0&1) patency of an epicardial artery in the 
presence of  impaired (TIMI grade 2) flow, or microvascular occlusion in the 
presence of angiographically normal flow (TIMI grade 3) successful reperfusion 
requires a patent artery with an intact microvascular network, conversely,  
reperfusion may occur despite an occluded epicardial artery due to the presence 
of collateral arteries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPECT perfusion images demonstrating myocardial infarction in different 
locations. A. An apical infarction (arrow) in the horizontal long axis (HLA) and 
vertical long axis (VLA) views.  B. Inferior Myocardial infarction in the short 
axis (SA) and Vertical long axis (VLA) views. In both studies the severity of the 
defects suggests minimal myocyte viability with in those territories. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TMP Grade 0 : No or minimal blush.  1. Stain present blush persists on next 
injection.  2. Dye Strongly persistent at end of wash out Gone by next injection. 
3.Normal ground glass appearance of blush. Dye mildly persistent at end of 
washout. Relation between TIMI, myocardial perfusion grade and mortality. 
TIMI myocardial perfusion grade 0 or no perfusion of myocardium is associated 
with highest rate of mortality if the stain of myocardium present (Grade 1). 
Mortality is also high. A reduction in mortality is seen if the dye enters the micro 
vasculature but is still persistent at the end of wash out phase (Grade 2). The 
lowest mortality rate is observed in those patients, with normal perfusion (Grade 
3) where the dye is minimally persistent at the end of wash out phase. 
 
 
 
PATENCY OF INFARCT RELATED ARTERY 
Angiography assessment 
 TIMI grading is used to assess the angiographic patency17. 
Grade of 
flow 
Definition 
0 Complete occlusion 
1 Penetration without perfusion. Coronary bed distal to 
occlusion fails to opacify completely 
2 Partial perfusion. Full but slow opacification of coronary bed 
distal to occlusion 
3 Complete perfusion 
 
 The 90 minutes patency rate from Gusto angiographic substudy was as 
follows; accelerated tPA 81% (54% grade III flow), combination treatment 
tPA-SK 73% (38% grade 3 flow), SK -iv heparin 60% (32% grade III flow), 
SK-subcutaneous heparin 54% (29% Grade 3 flow)6,7. 
 This clearly shows rt-PA is more effective than SK in bringing out a 
successful thrombolysis. 
CLINICAL DETECTION OF REPERFUSION 
 Sudden disappearance of chest pain is associated with successful 
thrombolysis. But this is difficult to assess in the CCU set up when most of the 
patients receive opioid analgesics. 
ECG: A BETTER PREDICTOR OF PERFUSION AT 
MICROVASCULAR LEVEL 
Recent studies have suggested that achievement of TIMI grade 3 flow in 
infarct related artery is not in and of itself indicative of successful myocardial 
reperfusion18. 
Myocardial contrast echocardiography was shown that even in the 
presence of normal epicardial flow after PTCA, impaired myocardial perfusion 
at tissue level can occur and is associated with poor recovery of LV function. 
Resolution of ST-Segment elevation on the surface ECG correlates  
closely with findings at contrast echocardiography19. Less than 50% resolution 
of ST-Segment elevation in the worst lead and no accelerated idioventricular 
rhythm has a sensitivity of 81%, specificity of 88%, positive predictive value of 
87%, negative predictive value of 83% and overall accuracy of 85% in 
predicting <TIMI 3 flow in infarct related vessel20. 
PROGNOSTIC SIGNIFICANCE OF ST RESOLUTION 
 James A. de Lemos et al. reported than 30 days mortality was 2.4% 
among patients who attain >70% ST resolution at 90 minutes where as it was 
8.1% in those with <30% ST resolution21. 
 Early and stable ST segment recovery is also associated with improved 
infarct zone wall motion at 48 hours22. 
FACTORS INFLUENCING THE SUCCESS OF THROMBOLYSIS 
1. Time interval between Pain onset to initiation of thrombolytic 
therapy. 
 This is the most important variable affecting the success of 
thrombolysis. 
 As time window increases not only more and more myocardium gets 
necrosed but also the thrombus gets organised and become more resistant to 
lysis. 
2. Structure of Thrombi 
 Thrombi rich in platelets are more resistant to lysis than fibrin rich 
thrombi. 
3. Circadian fluctuations 
 A morning resistance to thrombolytic therapy was observed by 
Braunwald et al.23 where as better success rate of thrombolysis was found by E 
Gold hammer et al. when SK was administered between 16.00-20.00 hours. 
4. Preinfarction Angina 
 Patients with acute myocardial infarction who have intermittent infarct 
related pain or unstable angina in the seven days preceding the infarction have 
faster coronary artery perfusion and smaller infarcts after thrombolytic therapy 
than patients without preinfarction angina24. 
 This may be an additional mechanism for the better prognosis in these 
patients, the other proposed mechanism being ischemic preconditioning. 
5. Sex 
 Eventhough mortality is high among women who develop Acute 
Myocardial Infarction; compared to men the rate of induced of coronary 
patency with thrombolytic drugs are comparable in women. 
 Menstruation is not a contra indication for thrombolytic therapy because 
menstrual bleeding is related more to sloughing of tissue than active bleeding. 
6. Cognitive heart failure and cardiogenic shock 
 No significant reduction in mortality occurs when Killip class IV 
patients an treated with SK. This may partly be due to low rate of adequate 
recanalization. 
7. Elderly patients 
 Risk of hemorrhagic complications are high in those aged above 75 
years. But the relative benefit seen with coronary thrombolysis is greatest for 
the elderly. 
REPERFUSION INJURY 
 Refers to detrimental metabolic, functional or structural consequence of 
restoring coronary flow that might be reduced, avoided or reversed by 
modifying the condition of reperfusion. 
LETHAL REPERFUSION INJURY 
 Refers to the death of myocardium that were still alive at the initiation of 
reperfusion. The mechanisms underlying the lethal reperfusion injury may be. 
1. Ischemia causes an intracellular osmotic load of accumulated 
catabolites like lactate inside the cardiacmyocytes leading to an 
increase in the osmolality of cytosol. After reperfusion enough 
plasma water bathes these cells. Osmotic diffusion of water into the 
cell causes rupture of cells. 
2. Cellular acidosis increases the intracellular excess of calcium, via 
Na-H+ exchange and Ca2-Na+ exchange. This calcium overload 
causes myofibrillar hypercontraction and rupture of sarcolemma. 
3. Excess free radical formation may damage the myocyte structure 
including sarcolemma. 
NON LETHAL REPERFUSION INJURY 
Stunning 
 It is a form of reversible post ischemic contractile dysfunction. 
Reperfusion arrhythmia 
 Is also considered a form of non lethal reperfusion injury. 
EFFECT OF REPERFUSION ON INFARCT REPAIR 
 Clinical studies has revealed that thrombolytic reperfusion performed 
more than 6 hours after symptom onset could still improve ventricular function 
and survival even though myocardial salvage need not be responsible for this 
effect. 
 This has been attributed to faster healing, reducing the complication like 
infarct expansion, aneurysm, as well as cardiac rupture. 
 Reperfusion gives inflammatory cells access to the infarcted region, 
with resultant degradation of deed cells which must be removed in order for 
repair to occur. 
REPERFUSION THERAPY: PTCA 
 Coronary angioplasty provides higher rates of TIMI grade III flow, is 
successful is >90% of patients and is associated with lower rates of reocclusion 
and post infarction ischemia than fibrinolytic therapy. 
 But it is unlikely that many centres will have the required facilities and 
experience to perform PTCA on a regular basis. 
 When possible triage of patients at high risk for mortality or severe LV 
dysfunction with signs of shock, pulmonary congestion, heart rate >100 bpm; 
SB<100 mmHg to facilities capable of performing cardiac catheterisation and 
rapid revascularisation should be considered. For patients less than 75 years it 
is a class I indication. When available without delay, consider primary PTCA 
for patients who are reperfusion candidates but have a risk of bleeding that 
contraindicates use of fibrinolytic therapy (Class IIa). 
RECURRENT CHEST PAIN 
 The most common cause of recurrent chest pain after AMI are coronary 
ischemia and pericarditis. 
POST INFARCTION ANGINA 
 Is defined as chest pain that is frequency similar to the original 
discomfort occurring at rest or with limited activity during hospitalisation 24 
hours or more after onset of Acute Myocardial Infarction. This pain may or 
may not be associated with ST-Segment, elevation or depression or with 
pseudonormalisation of inverted T waves on post myocardial ischemia ECG. 
The incidence of post Acute Myocardial Infarction angina is almost twice as 
high after non Q Myocardial Infarction than Q wave Myocardial Infarction (25-
35%). Thrombolytic therapy also lead to a high incidence of post infarction 
angina (35-45%), with a 12-15% incidence of reinfarction during the early 
experience with lytic therapy for reperfusion. 
APPROACH TO POST INFARCTION ANGINA 
 If there is persistent pain (lasting> 30 minutes), a reelevation of CK-MB 
and ST-T changes consider readministration of thrombolytic therapy. (rt-PA or 
r-PA). The other option is immediate coronary angiography and PTCA. 
COMPLICATIONS OF ACUTE MYOCARDIAL INFARCTION 
1. Dysrrhythmias 
Brady Cardia 
 Relatively common (30-40%) early in the course of Acute Myocardial 
Infarction especially in inferior infarction or after reperfusion of right coronary 
artery because of activation of vagal afferents that ultimately result in enhanced 
parasympathetic tone. 
 Atropine in doses of 0.5-1.0 mg is the drug of choice if hypotension and 
tissue hypoperfusion coexists. 
AV block, ventricular asystole 
 Atropine is useful for treatment of type I second degree AV block 
especially if complicating inferior wall MI and at times in third degree AV 
block of AV node in restoring AV conduction or for increasing junctional 
response rate. For ventricular asystole atropine is used in doses of 1.0 mg every 
3-5 minutes during CPR upto a maximum of 2.5 mg if asystole persists. 
Heart block 
 A heart block in the setting of Anterior Myocardial Infarction reflects 
extensive infarction and concomitant destruction of the conducting system and 
is associated with relatively high mortality. In contrast heart block with  
inferior Myocardial Infarction may primarily reflect ischemia of AV node 
rather than extensive tissue damage and so is associated with a better 
prognosis. 
Ventricular fibrillation 
 Ventricular Fibrillation can occur in 3-5% Acute Myocardial Infarction 
patients in the initial 4 hours. It is called primary VF. Mechanism is thought to 
be micro-reentry in the infarct zone. 
 Triggering factors include hypokalemia, hypomagnesemia, enhanced 
adrenergic tone, acidosis, increased intracellular calcium, increased free fatty 
acids and reperfusion induced production of free radicals. 
 Incidence of VF is decreased by the use of β-blockers. Prompt 
defibrillation using unsynchronised shock starting with 200J is the treatment of 
choice. If unsuccessful give another shock immediately with 200-300 J; if 
again persists, shock with energy level of 360J. 
Ventricular tachycardia 
 Polymorphic ventricular tachycardia causing hemodynamic collapse is 
treated with unsynchronised shock starting with 200J. Monomorphic 
ventricular tachycardia with hypotension (systolic BP<90mm Hg), pulmonary 
edema or angina should be treated with a synchronised shock with an energy 
level starting at 100J initially. 
 Hemodynamically stable ventricular tachycardia is treated with 
intravenous lidocaine 1-1.5 mg/kg IV bolus with supplemental doses of 0.5-
0.75 mg/kg every 5-10 minutes upto a maximum of 3 mg/kg if needed. This is 
followed by an infusion of 2-4 mg/min (30-50 µg/kg/min) for 24 hours. 
 Other dysrhythmia that can occur during Acute Myocardial Infarction 
are ventricular ectopics, atrial flutter and fibrillation, junctional rhythm. 
Accelerated idioventricular rhythm 
 Normally occur frequency during the first hours of Acute Myocardial 
Infarction and occur after thrombolysis is a reperfusion arrhythmia. 
Accelerated idioventricular rhythm should not be treated. When the rate exceed 
120/mt it should be considered as an automatic rhythm for which suppression 
with lidocaine should be considered. 
MECHANICAL COMPLICATIONS 
 Mechanical complications are Cardiogenic shock, papillary muscle 
dysfunction, papillary muscle rupture, ventricular septal rupture, cardiac 
rupture, ventricular aneurysm formation and pseudoaneurysm. 
CARDIOGENIC SHOCK 
 Cardiogenic shock may occur when 40% or more of left ventricle is 
infarcted. It is the most common cause of in hospital death in Acute Myocardial 
Infarction patients. Mortality rate is around 80%. The incidence of cardiogenic 
shock has decreased from 15% in the early 1970s to approximately 5-7%. This 
is attributed to use of thrombolytic therapy and better treatment of angina and 
ischemia. 
Characteristics of cardiogenic shock are 
1. Evidence of hypoperfusion: Cold, Clammy Skin, impaired 
mentation, oliguria. 
2. Systolic blood pressure < 80-90 mmHg. 
3. Left Ventricular End Diastolic pressure or Pulmonary capillary 
wedge pressure ≥ 18mm Hg. 
4. Evidence of primary cardiac abnormality. 
5. Cardiac index ≤ 1.8L/mt/m2 
Management of cardiogenic shock 
Maintenance of tissue perfusion 
 When systolic BP is more than 90 mmHg, intravenous dobutamine 
infusion is tried. When systolic pressure is below 80-90 mmHg dopamine is the 
preferred agent so as to bring the blood pressure to 90-100 mmHg. 
 If high doses of dopamine are necessary to maintain adequate perfusion, 
norepinephrine may be substituted for dopamine because nor epinephrine has 
more alpha agonist effect and lesser chronotropic and inotropic action of beta-
receptor stimulation. 
 Early mechanical revascularization by PTCA or CABG improves 
survival. In the waiting period, intra-aortic balloon counter pulsation may be 
used to buy time. Thrombolytic therapy should be administered if facilities for 
percutaneous intervention procedures are not available. 
PAPILLARY MUSCLE RUPTURE 
 It occur in 1% of myocardial infarction. Posteromedial papillary muscle 
is involved 6-12 times than that of anterolateral. Rupture occurs more often 
distally involving one or several of small heads of muscle. Usually manifests 2-
7 days after infarction with the development of pulmonary edema. Mitral 
valves replacement or repair is the treatment of choice. 
PAPILLARY MUSCLE DYSFUNCTION 
More common than rupture. Again posteromedial muscle is more often 
involved. Dysfunction may be transient during ischemia which can disappear 
with successful treatment. 
VENTRICULAR SEPTAL RUPTURE 
 Incidence is 1-3% of Acute Myocardial Infarction equally divided 
among anterior and inferior infarction. It occurs more often in first infarction 
and in the first week. Usually manifest by appearance of new harsh, 
holosystolic murmur along left sternal border and sudden clinical deterioration 
with hypotension and pulmonary congestion. Management is essentially 
surgical closure. 
CARDIAC RUPTURE 
 Free wall of ventricle is the most common site of rupture. Generally 
occurs within the first 2 weeks and may occur within 24 hours. It occur more 
often in first infarction, women, elderly, and with systemic hypertension 
particularly if there is no associated left ventricular hypertrophy. It generally 
presents as sudden unanticipated death. 
 Other complication that may occur are pulmonary thromboembolism 
and systemic embolism. 
CONTINUING MANAGEMENT 
 Uncomplicated Acute Myocardial Infarction patients can be transferred 
from CCU by 3rd day. 
MATERIALS AND METHODS 
PLACE OF STUDY 
 This study was conducted in the coronary care unit of Govt. General 
Hospital and Madras Medical College and Research Institute. 
PERIOD OF STUDY 
 From Jan 2005 to Feb 2006. 
DESIGN 
 Observational prospective cohort study of patients receiving 
streptokinase for acute myocardial infarction. A total of 83 patients were 
included in the study. 
METHODOLOGY 
A. Subject Selection 
1. Inclusion Criteria 
a. Presence of typical chest pain suggestive of Acute myocardial 
infarction along with ECG evidence of Acute myocardial 
infarction who were thrombolysed. Criteria for thrombolysis 
being 2 mm or more ST elevation in two contiguous precordial 
leads or 1 mm or more ST elevation in two contiguous limb 
leads. ECGs were recorded using Hewlett Packard Page write 
100 machine. 
b. Time window of 12 hrs from the onset of pain to the initiation of 
thrombolysis. 
2. Exclusion Criteria 
1. Late thrombolysis (more than 12 hrs from the onset of pain). 
2. Recurrent myocardial infarction. 
3. Presence of bundle branch block. 
4. Development of pericarditis 
DRUG THERAPY 
• All patients received streptokinase 1.5 million units in 100ml of Normal 
saline over 60 minutes. 
• Aspirin was given to all patients. 
• Use of heparin, β-blockers, ACE Inhibitors was according to CCU 
protocols, which was in accordance with ACC/AHA recommendations. 
DEFINITION OF SUCCESS OF THROMBOLYSIS 
• Success was defined by 
1. Clinical-complete subsidence of chest pain. 
2. Electrocardiographically-more than 50% ST resolution in a lead 
which showed maximum ST elevation initially. ST elevation is 
measured manually, 80 ms after J point from isoelectric line. 
Preceding PR segment is taken as isoelectric line. 
Patients were analysed for success of thrombolytic therapy at 90 minutes 
after initiation of thrombolytic therapy, applying the above mentioned criteria. 
Those who underwent successful thrombolysis were grouped into group A. 
Those with failed thrombolysis -Group B. 
The following parameters were analysed among them to know whether 
they influenced the outcome of thrombolysis. 
1. Age 
2. Gender 
3. Smoking status 
4. Drinking status 
5. Diabetes mellitus 
6. Systemic Hypertension 
7. Pre infarction angina 
8. Location of Myocardial Infarction 
9. Time of Streptokinase administration 
10. Time interval between the onset of pain and the initiation of 
thrombolytic therapy. 
DEFINITIONS 
Smoking 
 Patients are considered smokers if they were using tabocco for smoking 
in any form currently. Ex-smokers were defined as those who quitted smoking 
for more than 1 year back from the date of admission. 
Diabetes mellitus 
Patients were considered to be diabetic when 
1. Currently on oral hypoglycemic drugs and/or insulin or 
2. Plasma glucose> 126 mg% or 2 hr post prandial plasma glucose 
>200 mg% on more than 2 occasions. 
Hypertension 
 Patients were considered hypertensives when 
1. They are already on antihypertension medications. 
2. Medically documented history of blood pressure elevation more than 
140/90 mm H, on two occasions in the past. 
Preinfarction angina 
 Was defined as history of anginal pain during the preceding 7 days of 
the acute event causing hospital admission. 
Location of myocardial infarction 
Inferior wall infarction 
 Patients with ST elevation, with or without Q wave in leads II; III; aVF. 
are considered to have inferior wall infarction. 
Anterior wall infarction 
 Those people showing ST elevation with or without Q wave in any two 
contiguous leads from V1 - V6 and or LI and a VL are considered to have 
anterior wall infarction. 
FOLLOW UP 
 Patients were followed up until they were discharged from the hospital. 
 ECHO & Angiogram were done whenever possible. 
Statistical method 
 Univariate analysis was done by chi - square test and multivariate 
analysis by logistic regression. 
OBSERVATIONS 
A total of 83 patients were studied. Their age ranged from 31 - 76 years 
(mean 55.01) 68 of them were males (82%) and 15 females (18%); 20 of them 
were hypertensives (24%); 20 were diabetic (24%). 44 people were smokers 
(53%) and 29 (35%) used to consume alcohol. 23 patients experienced 
preinfarction angina (28%). 50 patients had anterior wall infarction (60%) and 
33 patients (40%) had inferior infarction. 
TABLE - 1 
 
CLINICAL DETAILS OF STUDY POPULATION 
ACCORDING TO THE OUTCOME OF THROMBOLYSIS 
 
Variables Sucess (%) Failed (%) 
Number 44 (53%) 39 (47%) 
Males 36 (53) 32 (47) 
Females 8 (53%) 7 (47%) 
Hypertension 11 (55%) 9 (45%) 
Diabetes 11 (55) 9 (45%) 
Smoking 22 (50%) 22 (50%) 
Drinking 20 (69%) 9 (31%) 
Preinfarction angina 9 (39%) 14 (61%) 
Time window   
0 - 4 hrs 21 (64%) 12 (36%) 
4 - 8 hrs 22 (55%) 18 (45%) 
8 - 12 hrs 3 (30%) 7 (70%) 
Age group   
< 60 yrs 30 (62%) 18 (38%) 
> 60 yrs 14 (40%) 21 (60%) 
Anterior wall infarct 20 (40%) 30 (60%) 
Inferior wall infarct 24 (72%) 9 (28%) 
 
 
TABLE - 2 
 
UNIVARIATE ANALYSIS FOR INFLUENCING FACTORS 
 
Sl. 
No. 
Variables Odds 
Ratio 
(OR) 
(X2)  
Chi - 
Square 
P value Comments
1. Age < 60 years 2.5 4.11 0.04 Significant 
2. Gender (female sex)  0.00 0.98  
3. Pre infarction 
angina 
0.46 2.43 0.11  
4. Diabetes 1.11 0.04 0.83  
5. Hypertension  0.04 0.4  
6. Smoking  0.34 0.56  
7. Drinking 2.78 4.50 0.03 Significant 
8. Infarct location 
(anterior) 
0.25 8.55 0.004 Significant 
 
 
TABLE - 3 
LOGISTIC REGRESSION ANALYSIS 
 
Variables OR P - value 
Age  < 60 yrs 0.4036 0.09 
Drinking 3.16 0.06 
Location (Inferior) 3.18 0.02 
Smoking 0.34 0.08 
 
 
  
68
36
15
8
20
11
20
11
44
22
29
20
23
9
48
30
35
14
0
10
20
30
40
50
60
70
N
o.
 o
f P
at
ie
nt
s
M
al
es
Fe
m
al
es
H
yp
er
te
ns
io
n
D
ia
be
te
s
Sm
ok
in
g
D
rin
ki
ng
Pr
e 
in
fa
rc
tio
n
A
ng
in
a
<6
0 
yr
s
>6
0 
yr
s
Variables
FIGURE - I
SUCCESS RATE WITH RESPECT TO INDIVIDUAL VARIABLES
Total Number
Successful
 64
55
30
0
10
20
30
40
50
60
70
Pe
rc
en
ta
ge
0-4 hrs. 4-8 hrs. 8-12 hrs.
Time Window
FIGURE 2
EFFECT OF TIME WINDOW ON SUCCESS RATE OF THROMBOLYSIS
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 DISCUSSION 
 The major finding of this study is that the location of the infarct 
significantly affects the outcome of thrombolysis. Those with inferior wall 
myocardial infarction have a 3.18 times chance of undergoing successful 
thrombolysis compared to anterior wall myocardial infarction (P=0.02). This is 
after adjustment for all confounding variable like time window, age, smoking 
status, gender, diabetes and hypertension. 
 25Similar observations were made by C.Michael Gibson, Sabina Murphy 
and E. Brawnwald et al. (TIMI studygroup). They found that TIMI grade III 
flow rates were lower for left coronary and circumflex artery compared to right 
coronary artery after thrombolytic therapy. 
 The reason for this differential response will be evident when we look 
into the physiology of coronary circulation in right and left coronary arteries. 
 Blood flow in right coronary artery is relatively independent of phases 
of cardiace cycle, being present in both systole and diastole. Where as flow in 
left coronary artery is almost absent during systole and may even be reversed in 
conditions of heightened micro vascular tone and left ventricular hypertrophy26. 
 The relatively thicker wall, the increased wall thickening during systolic 
contraction and higher intracavitary pressure of left ventricle may all produce 
higher intramyocardial pressure than that is observed in the thinner walled right 
ventricle, which is also subjected to lower filling pressures. 
 Moreover the extent of necrosis in anterior wall is more resulting in 
increased myocardial edema compared to inferior infarctions. This may further 
decrease the reperfusion rates in anterior infarctions. Yet another mechanism, 
may be, better drug delivery to right coronary artery and prolonged contact of 
streptokinase with the thrombus, resulting in more efficient fibrinolysis. 
ALCOHOL AND THROMBOLYSIS 
 Alcohol consumption has influenced the outcome of thrombolytic 
therapy in a favourable way. Univariate analysis revealed a success rate of 69% 
in drinkers versus 44% among non drinkers. (p = 0.03, OR = 2.78). This 
advantage of drinkers persisted after logistic regression analysis to remove the 
confounding factors, even though statistically not significant (OR = 3.16; 
p=0.06). 
 Alcohol is known to reduce coronary artery disease related mortality. In 
a meta analysis of all experimental studies that assessed the effects of moderate 
alcohol intake on concentrations of HDL cholesterol, apolipoprotein A1, 
fibrinogen, triglycerides, and other biological markers, Eric. B.Rimm, Paige 
William, Kerry Fosher et al27. concluded that 30g of alcohol per day would 
cause an estimated reduction of 24.7% in risk of coronary artery heart disease. 
 This better success rate observed in patients who consume alcohol may 
be easily explained by the effect of alcohol on hemostatic factors. In a study 
conducted on 631 apparently healthy male physicians, the plasmal level of tPA 
antigen were 10.9, 9.7, 9.1 and 8.1 ng/ml respectively in those who consumed 
alcohol daily, weekly, once a month and never28. 
 Studies have shown an effect on platelets also. Alcohol reduces platelet 
aggregation in response to most agonists like thrombin, ADP, epinephrine and 
collagen29. 
 By contrast in binge drinkers or in alcoholics after alcohol withdrawal, 
response to aggregation, especially that induced by thrombin, is markedly 
increased. This rebound phenomenon may explain ischemic strokes or sudden 
death known to occur after episodes of drunkenness. 
 Ethanol intake is also known to decrease blood fibrinogen level. Thus 
those who consume alcohol on a moderate basis are having better endogenous 
fibrinolytic response. 
INFLUENCE OF AGE OF THE PATIENT OF THROMBOLYSIS 
 Patients older than 60 years are found to have a lesser success rate in 
univariate analaysis. (X2 = 4.11, OR = 2.5, P = 0.04). After adjustment for 
other parameters in logistic regression, a statistically insignificant reduction in 
success rate is observed. 
 This shows that with respect to fibrinolysis elderly people donot behave 
differently from younger people. This is reflected in reduction in mortality rate 
among elderly after thrombolysis. In patients aged more than 75 years who 
were treated with Streptokinase in GISSI-2 trial, there was a reduction of 4.2 
fewer deaths per 100 patients than in controls. In ISIS - 2 there was 3.3 fewer 
deaths per 100 patients in those over 70 years of age who were treated4. 
 
GENDER 
 No statistically significant difference was noticed based on gender. 
Woodfield - SL, Lunderberg - CF, Topol EJ et al30. performed an angiographic 
study to find out the patency rate at 90 minutes in men versus women. At 90 
minutes TIMI - 3 flow rate was 39% in women and 38% in men, which was not 
statistically significant. But 30 day mortality was 13.1% in women versus 4.8% 
in men (P = 0.001). 
 Thus even though females have a poor outcome after myocardial 
infarction, they do not behave differently to thrombolytic therapy. 
DIABETES MELLITUS 
 In this study success rate of thrombolysis is not found to be different 
from non diabetic population. 
 Gray RP, Yudkin JS et al. found a reduction in reperfusion rates in 
thrombolysed diabetic patients31. 
 Diabetes is a prothrombotic state as reflected by the increased blood 
levels of fibrinogen, factor VII and Willebrand factor. These changes are even 
more increased if diabetic people happened to be smokers. 
 Flatelet function is also impaired in diabetics. They aggregate more 
readily to stimuli like ADP and collagen. Glycation of membrane proteins due 
to chronic exposure to high blood glucose levels32, change in fluidity of platelet 
membrane brought out by high concentration of cholesterol and triglycerides 
are the proposed mechanisms for these abnormalities. 
 On the otherhand patients with type II diabetes have profound 
suppression of fibrinolysis. Plasminogen activator inhibitor - I levels are high 
in type II diabetic people which is responsible for this effect. 
 Nevertheless thrombolytic therapy should be administered to diabetics 
with Acute Myocardial Infarction, because for every 100 diabetic patients 
treated with thrombolytic drugs four lives are saved. 
PREINFARCTION ANGINA 
 Felicita Andreoti; Vincenzo P et al. had demonstrated by angiographic 
method that those Acute Myocardial Infarction patients who experienced 
preinfarction angina within seven days preceding the acute event had a more 
rapid thrombolysis. Patency rates were higher at 35 minutes but at 90 minutes 
both were same33. 
 In this study success rate was same at 90 minutes in both groups. This is 
because ECG monitoring was not continuous in this study. Continuous ST 
segment monitoring may be needed to demonstrate the early achievement of 
patency in preinfarction angina patients. 
SMOKING 
 Outcome of thrombolysis is not affected by smoking. In this study there 
is a statistically insignificant trend towards a bad outcome. 34Cindy L. Gines, 
E.J. Topol et al. reported similar patency rates in smokers and nonsmokers at 
90 minutes (73% versus 74%). Smokers tends to have reduced inhospital 
mortality compared to nonsmokers. But this was due to the favourable baseline 
clinical and angiographic variables in smokers. Smokers tended to be younger 
and thrombosis of less critical atherosclerotic plaque was the culprit lesion in 
them. Smoking increases blood hematocrit, fibrinogen levels and platelet levels 
contributing to the hypercoagulable state promoting coronary thrombosis. 
Smokers are also found to have lesser fibrinolytic activity than nonsmokers. 
CIRCADIAN VARIATION 
 23Eugene Braunwald et al. noticed a circadian variation in efficacy of 
thrombolytic therapy, with better patency rates in the evening hours. This is 
due to circadian variation in the blood levels of PAI-I, which is highest in the 
morning hours. 
 In this study no such circadian variation was observed. Probable reasons 
for this discrepancy may be the shorter time window observed in patients 
presenting in morning hours as well as smaller sample size. 
PAIN TO STREPTOKINASE INTERVAL (TIME WINDOW) 
 This is the most powerful predictor of success rate. In this study also it 
is evident. Success rate was 64% in those patients thrombolysed within 4 hours 
from the onset of symptoms. The success rate decreased to 55%, when they 
were thrombolysed after 4 hrs but within 8 hours of onset of symptoms. 
Success rate came down to 30%, when streptokinase was administered after 8 
hours but within 12 hours. 
CONCLUSION 
• In this study the overall success rate of thrombolysis was 54%. 
• Inferior wall myocardial infarctions had a better success rate than 
anterior wall myocardial infarctions and it was statistically significant. 
• Smokers had a lesser success rate than non smokers, but it did not reach 
statistical significance. 
• Alcohol intake was associated with a better success rate eventhough 
statistically not significant. 
• Hypertensives didn't show any difference in the success rate. 
• Diabetics donot differ from non diabetics with respect to the success rate 
of thrombolysis. 
• There was a trend towards a worse outcome in those aged more than 60 
years. But it was not statistically significant. 
• Gender was not found to influence the success rate of thrombolysis. 
• Pre infarction angina had no effect on the success rate of thrombolysis. 
 
SUMMARY 
The study was conducted to evaluate the success rate of thrombolysis in 
acute myocardial infarction and the various factors influencing its out come. It 
was done by observational prospective cohort study of patients receiving 
streptokinase for acute myocardial infarction in coronary care unit, 
Government General Hospital, Chennai. The overall success rate of 
thrombolysis was 54%. Patients with inferior wall myocardial infarction had a 
better out come than anterior wall myocardial infarction. Alcohol, smoking and 
age were factors which influenced the out come, but were not statistically 
significant. Early thrombolysis had a better out come when compared to other 
predictors. Success rate was 64% in those patients thrombolysed within 4 hrs. 
from the onset of symptoms. Time window was found to be the most powerful 
factor influencing the out come of thrombolysis in patients with acute 
myocardial infarction. 
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  ABBREVIATIONS IN MASTER CHART 
 
 
Smo   - Smoking 
 
Dri   - Drinking 
 
HT   - Hypertension 
 
PIA   - Pre infarction angina 
 
DM   - Diabetes Mellitus 
 
TOS   - Time of onset of symptoms 
 
TSA   - Time of SK administration 
 
TW   - Time window 
 
REG   - Reggression 
 
EA   - Extensive anterior 
 
EF   - Ejection fraction 
 
→   - Pain persisted 
 
-   - Pain subsided 
 
PoIA   - Post Infarction Angina 
ABBREVIATIONS 
 
 LAD  - Left anterior descending artery 
 
 LCA  - Left Coronary artery 
 
 LCX  - Left circumflex artery 
 
 RCA  - Right Coronary artery 
 
 LV  - Left Ventricle 
 
 RV  - Right Ventricle 
 
 AMI  - Acute myocardial infarction 
 
 VF  - Ventricular fibrillation 
 
 VT  - Ventricular tachycardia 
 
 SK  - Streptokinase 
 
 PTCA  - Percutaneous transluminal coronary angioplasty 
 
 rtPA  - Recombinant tissue plasminogen activator 
 
 CABG - Coronary Artery by pass grafting  
 
 PAI - 1 - Plasminogen activator inhibitor - 1 
 
 PDGF  - Platelet derived growth factor 
 
 vWF  - Von Willebrand factor 
 
APSAC - Anisoylated plasminogen streptokinase activator 
complex 
 
LBBB - Left bundle branch block 
 
RBBB - Right bundle branch block 
PROFORMA 
 
Serial No.: 
 
Name :   Age :   Sex :  IP : 
 
Occupation :     Monthly Income : 
 
PERSONAL DATA 
 
1. Smoking 
 
Current Smoking Yes No  Ex.Smoker > 1 yr 
If yes, No.of 
Cigarettes 
   
 
2.  
Drinking Yes No  if yes ml/wk  
 
3. Other habits : Specify 
 
4. Life style 
 
Exercise regularly 
≥ 3 times / wk 
 Active  Sedentary 
 
5. Hypertension  Yes Bo If yes  1. Duration......................... 
       2. Treatment Regular Irregular 
 
6. Pre infarction angina 
 If yes  1. Within 24 hrs of infarct 
  2. Within 1 week of infarct 
 
7. Hyperlipidemias 
 
 a. Hypertriglyceridemia Treatment a. Diet alone 
        b. Drugs.................. 
 b. Hypercholesterolemia 
 c. Mixed 
Yes No 
Yes No 
8. Diabetes 
 
 
Duration  Insulin  
Type I Type II  OHA  
 
9. Other diseases - specify 
 
10.  
Medications Aspirin ACE I . blocker Others 
Dosage     
 
11. Family History: 
 
SCD AMI Stroke 
 
12. Time of onset of symptoms: 
 
0-6 a.m. 6-12 noon 12-6 p.m. 6-12 mn 
    
 
13. Physical Examination 
 
 Pulse   B.P.   Crackles 
 
 SIII   JVP   Rub 
 
14. Killip Class............................................................ 
 
15. Time of SK administration 
 
0-6 a.m. 6-12 noon 12-6 p.m. 6-12 mn 
    
 
16. Pain onset of SK interval in hrs 
 
0-4 hrs 4-8 hrs 8-12 hrs 
   
17. ECG on admission 
 
 1. Location of MI 
 
 
Extensive Anterior Antero Septal Anterolateral Inferior 
 
 2. Peak ST elevation in millimeters: 
 
18. ECG at 90 mts after SK therapy 
  Maximal ST elevation in millimeter 
 
19. Percentage ST Resolution 
 
20. Clinical condition at 90 mts 
 
 a) No Angina 
 b) Decreased 
 c) Persistent with same intensity 
 
21. Arrhythmias if any during thrombolysi: 
 
22. Other drugs used 
 
Heparin  
NTG  
Blockers  
Ionotropics  
 
23. Thrombolysis successful? 
 
24. Post infarction angina 
 
 If yes Intervention  resorted to 
 
 1. NTG  2. Blockers 3.Ca++ Channel Blockers 
 4. Emergency PTCA 5. Others 
 Other Events and Intervention if any: 
Yes No 
Yes No 
25. Laboratory data 
 
 1. Hb  TC  PLE  ESR 
 
 2. Urea  3. Creat 
 
 
 4. Blood sugar  5. Na+   C1- 
      K+   HCO3  
 
    Admission  6hrs  24 hrs 
 
6.  
CPK  Total    
CPK - MB    
 
 
7. ECHO 
 
8. Angiogram: 
 
 
9. Others if any 
 
10. Follow up: 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
ge Sex Smo Dri HT PIA DM TOS TSA TW Kil's 
Class 
Location of MI ST↑ 
(Adm) 
ST ↑ 
90mts 
% ST 
REG 
Clini 
90mts
Out 
come 
Arrhy E
39 M Y Y N Y N 11 am 3.45 
pm 
5.45 Hr I EA ST ↑ V1- 
V6LI;aVl 
4 3 25% - F  EF
44 M Y Y N N N 8 am 12.30 
pm 
4.30 I Inf ST ↑ II; 
III; aVF 
4 3 100% - S Hypotension 
Brady cardia
N f
EF
70 F N N N N N 11 am 2 pm 3 I Inf ST ↑ II; 
III; aVF 
11 10 90 - S  
57 M N N Y N N 5.30 pm 6.20 
pm 
1 I ANT ST ↑ V1 - V4 8 3 62 - S  EF
59 M Y N Y N Y 11 am 4.10 
pm 
5 I Ant ST ↑ V1 - V5 4 3 25 - F  EF
m
d
70 M N N Y N N 12 mn 12 
noon 
12 I EA ST ↑ V1 - V6 
aVL LI 
6 4 33 - F  
72 M Y N N Y N 12.30 pm 6.30 
pm 
6 I Inf ST ↑ II; III; aVF 2.5 2 25 - F  
fu
40 M Y Y N N N 8.30 pm 12.40 
am 
4 I Ant ST ↑ V1 - V4 15 4 73 - S VF-defi 
brillated 
EF
51 M Y Y N N N 10 pm 1.15 
am 
3.15 I Ant ST ↑ V1 - V6 13 6 58 - S  EF
mod
50 M Y Y N N N 6.30 am 11.15 
am 
5 I EA ST ↑ V1 - V6; 
Ll'aVL 
6 2 66 - S  EF
mod
50 M N N N N N 5 pm 8 pm 3 I Inf with RVMI ST ↑ 
II'III' aVF' V4R 
6 1 83 - S  EF
triv
70 F N N N N N 7 am 8.30 
am 
1.30 I Inf+Lat Post ST ↑ 
II; III; aVF; V5, V6 
4 1 75 - S  EF
M
35 M N Y N N N 6.30 am 10.30 
am 
4 III Ant ST ↑ V1-V4 5 2 60 - S  Nor
EF
60 M Y N N N N 3 pm 6.50 
pm 
3.15 I EA.ST ↑ V1-V6 L1; 
aVL 
8 5 37 - F  EF
m
68 F N N N N N 1.30 pm 5.50 
pm 
3.45 I Inf. with RVMI 6 1 82 - S  EF
M
d
65 M N N N Y N 2 am 4.50 
am 
2.15 I Ant ST ↑ V1-V6  12 8 33 - F  3
65 M Y N N Y N 1 pm 7.40 
pm 
6.40 I Ext. Ant 6 4 33 - F  EF
59 M Y Y N N N 9 pm 10.50 
pm 
1.15 I Inf. with RVMI 6 4 33 - F  45%
LV
71 M N N N N N 3 pm 9.30 
pm 
6.30 I Ant ST ↑ V1-V6  6 4 33 - F  EF
mild
thr
ge Sex Smo Dri HT PIA DM TOS TSA TW Kil's 
Class 
Location of MI ST↑ 
(Adm) 
ST ↑ 
90mts 
% ST 
REG 
Clini 
90mts
Out 
come 
Arrhy E
60 M Y N N N N 7 am 1.40 
pm 
6.40 I Ant ST ↑ V1-V6  5 5 0 - F  EF
46 M Y Y N Y Y 10 am 2 pm 4 I Ant ST ↑ V1-V6  6 4 33 - F VPDST EF
55 F N N N Y N 9 am 2.30 
pm 
5  EA.ST ↑ V1-V6 L1; 
aVL 
3 2 33 - F  EF
51 M N Y Y Y N 8 pm 12.30 
am 
4.30 I Inf ST ↑ II; III; aVF 2 1 50 - S  Nor
EF
40 M Y Y N N N 3 am 7.45 
am 
4.45 I Ant ST ↑ V1-V5  6 3 50 - S VT EF
60 F N N N N Y 11 pm 1 am 2 I Inf with RVMI ST ↑ 
III'III' aVF' V4R 
3 2 33 - F  EF
70 M N N N N Y 4 pm 10 pm 6 I Ant ST ↑ V1-V3  8 4 50 - S  EF
58 M N N N N N 10 am 1.15 
pm 
4 I Inf ST ↑ II; III; aVF 7 2 71 - S  EF 
50 M Y Y N N N 7.30 am 8.45 
am 
1.15 I Inf with RVMI ST ↑ 
III'III' aVF' V4R 
4 0 100 - S  EF
45 M Y Y N N N 11 am 3.30 
pm 
4.30 I Inf with RVMI ST ↑ 
III'III' aVF' V4R 
3 1 66 - S  EF
60 M Y N Y N N 6 pm 11 pm 5 II EA.ST ↑ V1-V6 L1; 
aVL 
  0 - F  
47 M N N Y N Y 3.30 pm 1 am 9.30 I Ant ST ↑ V2-V6  6 4 33 - F Hypo Brady 
Cardia 
EF
52 M N N Y Y N 10 am 2 pm 4 I Ant ST ↑ V5-V6  L1; 
aVL 
2 1 50 - S  46
LV
45 M N N N N N 9 am 3 pm 6 I Inf with RVMI ST ↑ 
III'III' aVF' V4R 
3 1 66 - S  5
50 M N Y Y N N 12 noon 2.30 
pm 
2.30 I Inf with RVMI ST ↑ 
III'III' aVF' V4R 
9 2 77 - S  
62 M N N N N N 11.30 am 9.20 
pm 
11 I Ant ST ↑ V1-V3 4 4 0 - F  45
LV
50 M Y Y N N N 5 pm  9.20 
pm 
4.20 Hr. I Ant ST ↑ V1-V6 14 7 50 - S  5
40 M Y Y N N Y 12.30 am 3.30 
am 
3. I Inf II; III; aVF' 
ST ↑ 
2 0 100 - S  6
57 M Y N N N N 11 noon 3.30 
am 
3.30 I Ext Ant ST ↑ V1-V6 
aVL; I 
11 2 72 - S  45
42 F N N N Y N 8 am 11.15 
am 
3.15 I Inf+RVMI ST ↑ II, 
III, aVF, V4R 
2.5 2 20 → F  4
49 M Y Y Y N N 12 
M.Night 
2.30 
am 
2.30 I Inf II; III; aVF' 
ST ↑  
2.5 0 100 - S  
65 M Y Y N Y N 7 pm 1 am 6 II EA.ST ↑ V1-V6 L1; 
aVL 
5 3 40 - F VPDs+ AVR+ 5
60 F N N N N N 5 pm 3.20 
am 
10.20 I Ant ST ↑ V1-V6 2 1.5 25 → F  Mild
4
ge Sex Smo Dri HT PIA DM TOS TSA TW Kil's 
Class 
Location of MI ST↑ 
(Adm) 
ST ↑ 
90mts 
% ST 
REG 
Clini 
90mts
Out 
come 
Arrhy E
72 M N N N N N 10 am 10 pm 12 II EA.ST ↑ V1-V6 L1; 
aVL 
7 7 0 - F  
60 M N N Y N Y 11 am 10 pm 11 I Ant ST ↑ V1-V6 6 4 33 - F  
60 F N N N N N 11 am 2.45 
pm 
4.45 I Inf ST ↑ II; III; aVF 2 0 100 - S  40%
LV
70 M Y N N Y N 4 pm 6.15 
pm 
2.30 I Ant ST ↑ V1-V4 4 3 25 - F  50
LV
36 M Y T N N N 8 pm 10.50 
pm 
2.50 I Inf ST ↑ II; III; aVF 2 2 0 - F  
44 M Y N Y Y N 11 pm 1 am 2 I Inf ST ↑ II; III; aVF 3 1 66 → S  EF
60 M Y Y Y N N 5 am 3.30 
pm 
10.30 
Hr. 
I Ant ST ↑ V1-V6 13 2 84 - S - 50
76 M N Y N Y Y 3.30 pm 7 pm 3.30  I Inf ST ↑ II; III; aVF 1 0.5 50 - S VT 5
51 M Y Y N N N 3 am 3.55 
am 
0.55 
mts 
I Inf ST ↑ II; IIII; aVF; 
aVR 
8 10 0 - F  5
53 M Y N N Y N 3.30 pm 5.30 
pm 
2  I Ant ST ↑ V1-V5 3 2 33 - F  7
52 M Y Y N N N 7 am 4.30 
pm 
9.30 I Inf+RVMI ST ↑ II; 
III; aVF, V4 R 
7 2 71 - S  4
53 M Y Y N N Y 6.30 am 8.30 
am 
2 I Ant ST V1-V5 8 6 25 - F  3
31 M Y Y N N N 10 am 4 pm 6 II Ant V1-V5 ST ↑ 11 7 36 - F VF 40%
53 M Y N N N N 11 am 8.30 
pm 
9.30 I Ant V1-V5 ST ↑ 4 3 25 - F  
50 M Y N N Y N 2 am 6.15 
am 
4.15 I Ant V1-V3  6 4 33 - F  4
65 F N N N N N 8 am 12.25 
pm 
4.25 I Ant ST ↑ V1-V4 3 2 33 - F  4
52 M N N N N N 9.30 am 3.50 
pm 
6.20 I Ant ST ↑ V1-V4 5 3 40 - F  5
58 M N N Y N N 1.30 pm 4.30 
pm 
3 I Inf with RVMI ST  ↑
II; III aVF; V4R 
7 8 0 - F  7
64 F N N N N Y 1 pm 6.40 
pm 
5.40 I Inf with RVMI ST  ↑
II; III aVF; V4R 
5 2 60 - S  
58 M Y N N N N 1 am 8.50 
am 
7.50 hrs I EA.ST ↑ V1-V6 L1; 
aVL 
12 2 83 - S VT 24 Hr. & 
48 Hrs. 
62 M Y N Y N N 7 pm 9.30 
pm 
2.30 I Ant ST ↑ V1-V3 3 3 0 - F - 47%
LV
32 M Y Y N N N 6.30 am 12.45 
pm 
6.15 I EA.ST ↑ V1-V6 L1; 
aVL 
5 2.5 50 - S - 
60 F N N Y N N 2 pm 11.25 
pm 
9.20 I Inf with RVMI ST  ↑
II; III aVF; V4R 
2 2 0 - F - 
ge Sex Smo Dri HT PIA DM TOS TSA TW Kil's 
Class 
Location of MI ST↑ 
(Adm) 
ST ↑ 
90mts 
% ST 
REG 
Clini 
90mts
Out 
come 
Arrhy E
64 M Y N N N Y 8.30 pm 12 
M.night 
3.30 II Ant ST ↑ V1-V6 7 3 57 - S VPD+ 4
47 M Y N Y Y Y 11 am 6.30 
pm 
7.30 II Ant ST ↑ V1-V6 6 7 0 → F  
67 F N N Y N Y 10 am 2.10 
pm 
4.10 I Inf ST ↑ II; III aVF 5 2 60 - S VPDS; Trans 
CHB 
5
75 M N N N Y N 3 pm 11.30 
pm 
8.30 I Ant V1-V6 9 4.5 50 - S  
62 M N N N N Y 1 pm 4 pm 3 I Inf. Post. Lat, ST↑ 
II; III aVF; V5-V6 
ST↓ V1-V3 
3 0 100 - S  
75 M N N N N Y 1 am 5 am 4 I Ext. Ant V1-V6; aVL, 
L1 
10 6 40 - F - 
55 M Y N N Y Y 6 am 8.30 
am 
2.30 II Ext. Ant V1-V6; aVL, 
L1 
15 5 66 - S - 6
52 M Y N N N Y 10.30 am 3.45 
pm 
5.15 I Inf. II; III aVF ST↑ 5 0 100 - S  6
62 F N N N Y Y 6 am 10.30 
am 
4.30 hrs I ST↑ V1-V5; Ant 3 2 33 - F  EF
60 M Y Y N N Y 5 pm 10.45 
pm 
5.45 I EA, ST ↑ V1-V6 L1; 
AVL Ant. 
15 7 53 - S  
44 M N N N Y N 4.30 am 5.30 
am 
1 I ST↑ II; III; aVF Inf. 1 0 100 - S  
59 M N N N N N 2 pm 5.15 
pm 
3.15 II ST↑ II; III; aVF Inf. 2 0 100 - S  6
38 M Y Y N Y N 6.30 pm 10.30 
pm 
4 I Ant ST↑ V1-V6 7 3 57 - S RBBB 
transient 
biftasicular 
block 
6
60 M Y Y Y Y N 1 am 3 am 2 I Inf. ST↑ II; III; aVF 3 3 0 → F  4
50 M Y N N N N 12 noon 3 pm 3 I EA ST↑ v1-v6 L1 
aVl 
9 9 0 - F Brady cardia 3
50 M Y Y N N N 1 pm 2.30 
pm 
1.30 I Inf. ST↑ V1-V6 L1 
aVF V4R 
4 0.5 87 - S  5
60 F N N Y Y N 10 pm 3.30 
am 
5.30 I EA ST↑ L1 aVL V1-
V5 
5 1.5 70 - S  6
45 M N N N Y N 5 am 10 am 5 I EA ST↑ aVL V1-V6 3 2 33 - F  58
 
 
 
 
